Latest news
{{'2025-11-26T13:00:00Z' | dateFormatFilter}}
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
{{'2025-11-25T11:24:50Z' | dateFormatFilter}}
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
{{'2025-11-24T11:21:08Z' | dateFormatFilter}}
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
